Treviamet®

Treviamet®

Therapeutic Segment: Anti-Diabetic

Generic Name: Sitagliptin phosphate monohydrate + Metformin HCI

Indication:

For:

  • As initial therapy in patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise do not provide adequate glycemic control.
  • As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus inadequately controlled on Metformin HCl or Sitagliptin alone or in patients already being treated with the combination of Sitagliptin and Metformin HCl.
  • In triple combination with a sulphonylurea as an adjunct to diet and exercise in patients with type 2 diabetes mellitus inadequately controlled on their maximal tolera ted dose of Metformin HCl and a sulphonylurea.
  • In triple combination with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of Metformin HCl and a PPARγ agonist.
  • In patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in combination with insulin.

Available as:

Tablets
  • 50MG + 500MG
  • 50MG + 850MG
  • 50MG + 1000MG